Eliminating Barriers
to Global Vaccination

Approach

VitriVax is a formulation technology company engineering innovative solutions to maximize global accessibility and utility of human and animal vaccines – vaccines that save lives and protect our world from preventable disease.

Approach

VitriVax is a formulation technology company engineering innovative solutions to maximize global accessibility and utility of human and animal vaccines – vaccines that save lives and protect our world from preventable disease.

Technology

A Complex Challenge, A Novel Solution
Vaccines provide unique benefits for human health, but their broad use often is limited by two central technological challenges:

1. Maintaining thermostability during transport and storage

2. The need to administer multiple doses to provide a robust immune response against infection or disease

VitriVax has engineered its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA) technology platform to enable thermostable, single-shot vaccines across a broad range of indications, while maintaining or potentially even enhancing the immune response of vaccines. ALTA can be applied to a wide variety of vaccine antigens and adjuvants to protect against thermal and chemical degradation and enable controlled release, incorporating prime doses + additional booster doses in a single-shot administration. These technologies may also facilitate co-formulation of multiple otherwise incompatible antigens in a single injection.

ALTA Technology Platform
Thermostability + Single-Shot Administration

Thermostability: We use a spray drying process to embed antigens and adjuvants in a sugar glass matrix, protecting them against thermal and chemical degradation at temperatures as high as 70° Celsius (158° Fahrenheit) for months, eliminating the need for cold storage and complex distribution.
Single-Shot Administration: We utilize Atomic Layer Deposition (ALD) to apply nanometer-thick, precision coatings of protective metal oxides on the surface of antigen and adjuvant-containing spray dried microparticles, providing timed release of doses up to 6 months after injection.

ALTA uses highly scalable, commercially available equipment and ingredients that are already common in pharmaceuticals and generally recognized as safe (GRAS).

ALTA-enabled vaccines are engineered for extended shelf life allowing them to be easily transported anywhere in the world, stockpiled or distributed preventatively as part of emergency or military supplies. Creating a single-shot vaccine greatly increases adherence, with larger numbers of people being vaccinated and fully protected. The combination of reduced cold chain requirements during storage and transportation with single-shot administration enables vaccines to more easily reach underserved populations and geographies, helping to prevent disease and save lives.

Team

VitriVax is led by a world-class team of scientists, engineers and entrepreneurs with expertise in vaccine development, virology and chemical engineering and a commitment to eliminating barriers to global vaccination.
Robert Garcea, MD
Co-Founder
Theodore Randolph, PhD
Co-Founder
Matthew Raider
Chief Executive Officer
Romulo Colindres, MD, MPH
Chief Medical Officer
Bryan Steadman
Chief Technical Officer
Kyle Stults
Head of Finance and Administration
Robert Garcea, MD
Co-Founder
Theodore Randolph, PhD
Co-Founder
Matthew Raider
Chief Executive Officer
Romulo Colindres, MD, MPH
Chief Medical Officer
Bryan Steadman
Chief Technical Officer
Kyle Stults
Head of Finance and Administration

Partnerships

VitriVax partners actively with some of the world’s leading vaccine discovery, development and manufacturing companies to expand the application of its technology and prevent disease in humans and animals. To learn more, please contact us.

Partnerships

VitriVax partners actively with some of the world’s leading vaccine discovery, development and manufacturing companies to expand the application of its technology and prevent disease in humans and animals. To learn more, please contact us.

Join Us

We are headquartered in Boulder, Colorado and are actively seeking candidates to join our growing team as we continue to expand vaccine access through VitriVax’s ALTA platform and partnerships with vaccine developers and manufacturers. We value innovative thinking and approaches to problem solving, enthusiastic collaboration, and a strong entrepreuneurial mindset.

News/Media

Learn more about VitriVax and its ALTA platform.
07/07/2021

VitriVax draws big partnerships — and backing from Adjuvant Capital

For as long as a prime-boost vaccine regimen — a model that’s been front and center in the fight against Covid-19 — has been deployed, scientists have been looking for…
07/07/2021

VitriVax Announces Series A Financing to Further Demonstrate Feasibility of its Thermostable, Single-Dose Vaccine Technology, Aiming to Make Life-Saving Biologics Widely Accessible to Underserved Populations Globally

Investment from Adjuvant Capital to support the development of VitriVax’s ALTA™ platform, accelerate partnerships, and develop high-value public health vaccines and therapeutics BOULDER, Colo., July 7, 2021 /PRNewswire/ — VitriVax, developer of a…
View All News

    Contact

    We’d like to hear from you.

    Contact

    We’d like to hear from you.

    3415 Colorado Avenue, Boulder, CO 80303
    info@vitrivaxbio.com